Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV‑2 Mpro)

MLA

Pedro Henrique R. de A. Azevedo, et al. “Statine-Based Peptidomimetic Compounds as Inhibitors for SARS-CoV-2 Main Protease (SARS-CoV‑2 Mpro).” Scientific Reports, vol. 14, no. 1, Apr. 2024, pp. 1–16. EBSCOhost, https://doi.org/10.1038/s41598-024-59442-4.

APA

Pedro Henrique R. de A. Azevedo, Priscila G. Camargo, Larissa E. C. Constant, Stephany da S. Costa, Celimar Sinézia Silva, Alice S. Rosa, Daniel D. C. Souza, Amanda R. Tucci, Vivian N. S. Ferreira, Thamara Kelcya F. Oliveira, Nathalia R. R. Borba, Carlos R. Rodrigues, Magaly G. Albuquerque, Luiza R. S. Dias, Rafael Garrett, Milene D. Miranda, Diego Allonso, Camilo Henrique da S. Lima, & Estela Maris F. Muri. (2024). Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV‑2 Mpro). Scientific Reports, 14(1), 1–16. https://doi.org/10.1038/s41598-024-59442-4

Chicago

Pedro Henrique R. de A. Azevedo, Priscila G. Camargo, Larissa E. C. Constant, Stephany da S. Costa, Celimar Sinézia Silva, Alice S. Rosa, Daniel D. C. Souza, et al. 2024. “Statine-Based Peptidomimetic Compounds as Inhibitors for SARS-CoV-2 Main Protease (SARS-CoV‑2 Mpro).” Scientific Reports 14 (1): 1–16. doi:10.1038/s41598-024-59442-4.